Charles River Laboratories International, Inc. (CRL)
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Is Now the Right Time to Hold on to Charles River Stock?
CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRL Gears Up for Q4 Earnings: Here's What You Need to Know
Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio.
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line?
Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform.
Should You Retain Charles River Stock in Your Portfolio Now?
CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors.
Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
CRL Stock to Gain From the Global Biotech Incubator Program Launch
Charles River's new initiative specifically caters to early-stage biotechnology developers.
Is it the Right Time to Hold Charles River Stock in Your Portfolio?
Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts.
Charles River (CRL) International Revenue in Focus: Trends and Expectations
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL ) Q3 2024 Earnings Conference Call November 6, 2024 9:30 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - President and Chief Executive Officer Flavia Pease - Chief Financial Officer Conference Call Participants Max Smock - William Blair & Company Matthew Sykes - Goldman Sachs David Windley - Jefferies Group LLC Eric Coldwell - Robert W. Baird & Co. Justin Bowers - Deutsche Bank Dan Leonard - UBS Group AG Elizabeth Anderson - Evercore ISI Michael Ryskin - BofA Securities, Inc. Tejas Savant - Morgan Stanley Casey Woodring - JPMorgan Chase & Co. Luke Sergott - Barclays Patrick Donnelly - Citigroup Inc. Operator Please stand by, we're about to begin.
